journal article·2026-04

A novel ESIPT based fluorescent probe for L-BPA sensing

Yuanfeng Qi, Yongjie Lai, Le Wang, Shibo Sun, Yang Ji, Yingbo Li, Junfeng Wang

Dyes and Pigments· Volume 247
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Boron Compounds in Chemistry · Organoboron and organosilicon chemistry · Boron and Carbon Nanomaterials Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (38)

Show source-provided references
1. Redox mechanisms underlying the cytostatic effects of boric acid on cancer Cells-An issue still open10.3390/antiox12061302 ↗
2. Recent developments in organoboron chemistry: old dogs, new tricks10.1016/j.chempr.2017.05.008 ↗
3. Boron chemicals in drug discovery and development: synthesis and medicinal perspective10.3390/molecules27092615 ↗
4. Boron in drug design: recent advances in the development of new therapeutic agents10.1016/j.ejmech.2019.06.092 ↗
5. Spotlight on tavaborole for the treatment of onychomycosis
6. Development of the proteasome inhibitor Velcade (Bortezomib)10.1081/CNV-120030218 ↗
7. T. Robak, H. Huang, J. Jin, J. Zhu, T. Liu, O. Samoilova, H. Pylypenko, G. Verhoef, N. Siritanaratkul, E. Osmanov, J. Alexeeva, J. Pereira, J. Drach, J. Mayer, X. Hong, R. Okamoto, L. Pei, B. Rooney, H. van de Velde, F. Cavalli, Bortezomib-Based therapy for newly diagnosed mantle-cell lymphoma, N Engl J Med 372(10) 944-953.10.1056/NEJMoa1412096 ↗
8. Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-Year carcinogenicity studies10.1177/1091581814545245 ↗
9. Ixazomib – the first oral proteasome inhibitor10.1080/10428194.2018.1523398 ↗
10. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection10.1111/exd.14722 ↗
11. Structural basis and binding kinetics of vaborbactam in class A β-Lactamase inhibition10.1128/AAC.00398-20 ↗
12. Proposal of recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for neutron capture therapy10.1093/jrr/rrad064 ↗
13. Identification of borinic esters as inhibitors of bacterial cell growth and bacterial methyltransferases, CcrM and MenH10.1021/jm050676a ↗
14. Drugs for BNCT: BSH and BPA
15. Boron chemistry for medical applications10.3390/molecules25040828 ↗
16. Handbook of Boron science
17. Gao · 2018 · 371
18. Hosmane · 2011
19. Advancements in the synthesis and biological properties of carboranes and high-boron related compounds: a comprehensive exploration with emphasis on BNCT applications
20. Boron neutron capture therapy of cancer: current status and future prospects10.1158/1078-0432.CCR-05-0035 ↗
21. Clinical viability of Boron Neutron capture therapy for personalized radiation treatment10.3390/cancers14122865 ↗
22. Molecular mechanisms of specific cellular DNA damage response and repair induced by the mixed radiation field during Boron neutron capture therapy10.3389/fonc.2021.676575 ↗
23. Application of a lab-made ternary Fe-Cr-Al coil vaporizer coupled to ICP OES for boron determination in powdered food after the sample preparation in alkaline media10.1016/j.microc.2020.104875 ↗
24. Trace analysis of potentially mutagenic boronic acids and esters in drug substance by ICP-MS10.1021/acs.oprd.6b00325 ↗
25. Fluorescent sensing for boronic acid derivatives: design, synthesis, mechanism, application and perspective in Boron Neutron Capture Therapy (BNCT)10.1016/j.dyepig.2024.112561 ↗
26. Synthesis and mechanistic investigation of BPA fluorescent probes targeting BPA for potential application in Boron Neutron Capture Therapy (BNCT)10.1016/j.saa.2024.125318 ↗
27. Li · 2022
28. Imine–Amine tautomerism vs keto–enol tautomerism: acceptor basicity dominates over acceptor electronegativity in the ESIPT process through a six-membered intramolecular H-Bonded network10.1021/acs.jpca.9b08646 ↗
29. Calculation of the detection limits by explicit expressions10.1016/j.apradiso.2017.02.014 ↗
30. Development of a 2 - (2 - Hydroxyphenyl) -1H-benzimidazole-Based fluorescence sensor targeting boronic acids for versatile application in boron neutron capture therapy10.3390/cancers15061862 ↗
31. Fluorescence quenchers for hydrazone and oxime orthogonal bioconjugation10.1021/bc300344b ↗
32. Peripheral substituent effect on ‘turn-on’ fluorescence of BODIPY derivatives for sensing benzene moieties10.1016/j.molstruc.2024.140253 ↗
33. An environmentally sensitive zinc-selective two-photon NIR fluorescent turn-on probe and zinc sensing in stroke10.1016/j.jpha.2023.11.010 ↗
34. An sp-hybridized all-carboatomic ring, cyclo[18]carbon: electronic structure, electronic spectrum, and optical nonlinearity10.1016/j.carbon.2020.05.023 ↗
35. Multiwfn: a multifunctional wavefunction analyzer10.1002/jcc.22885 ↗
36. Red-shifted optical absorption induced by donor–acceptor–donor π-extended dibenzalacetone derivatives10.1039/D4RA07256A ↗
37. Enlarging the stokes shift by weakening the π-Conjugation of cyanines for high signal-to-noise ratiometric imaging
38. Pharamacokinetic modeling for boronophenylalanine-fructose mediated neutron capture therapy: 10 B concentration predictions and dosimetric consequences